– The University of California, San Diego (UCSD) School of Medicine and Cofactor Genomics are collaborating to boost patient outcomes in cancer care using precision medicine techniques.
The partnership will aim to improve a physician’s ability to predict tumor response to immunotherapy, specifically in recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC).
The current clinical care pathway for recurrent and metastatic head and neck cancers relies on outdated technologies for treatment decisions. Providers need new clinical decision support tools that can help them make confident treatment choices.
“Predicting tumor response prior to treatment is a necessary part of the precision medicine challenge,” said Ezra Cohen, MD, Chief of the Division of Hematology‐Oncology at the UCSD Moores Cancer Center. “Working with immune checkpoint inhibitors, a class of therapies that are already approved and proven to work in a subset of patients, is a low-risk, high-reward approach.”
Through the partnership, UCSD will provide Cofactor Genomics with access to patient specimens and clinical metadata. Data generated in this partnership will further expand on innovative methods of predicting responders to therapy.
“Cofactor is approaching diagnostic development in a number of ways that are unique. Integrating multiple immune signals into a single clinical decision simultaneously simplifies and expands how we leverage this information,” said Cohen.
The collaboration will leverage the expertise of physicians at UCSD, facilitating the development of advanced solid tumor therapeutics.
“The UCSD Moores Cancer Center is well-recognized as both a leader in